Dr. Reddy's Laboratories Limited filings document its U.S. reporting as a foreign private issuer with American depositary receipts listed on the New York Stock Exchange. Recent Form 6-K reports furnish exchange intimations and exhibits submitted to Indian exchanges and the NYSE, including board-meeting notices and other current-report disclosures.
The filing record centers on Rule 13a-16 and 15d-16 submissions, Form 20-F reporting status, governance communications, and public-company notices tied to Dr. Reddy's pharmaceutical operations and securities across India and the United States.
Dr. Reddy’s Laboratories Limited will release its Q1FY27 results for the quarter ended June 30, 2026 on Wednesday, July 22, 2026, following a meeting of its Board of Directors. The results will be disseminated through stock exchanges, media, the company website, and email.
On the same day, the company’s management will host an earnings call at 19:30 PM IST / 10:00 AM ET to discuss financial performance. A press meet presentation and the audio recording and transcript of the call will be made available on the company’s website.
Dr. Reddy’s Laboratories Limited, a foreign private issuer, submitted a Form 6-K noting that an audio recording of its conference call held on July 9, 2026 is available online. The company provided a specific web link to the recording for the information and records of investors and stock exchanges.
Dr. Reddy’s Laboratories reported that certain batches of its semaglutide product were found to be out of specification due to an issue linked to the active pharmaceutical ingredient used. The company is investigating the root cause and implementing measures to protect product quality.
As a result, commercial supplies of semaglutide will be delayed for a period of time. The company stated there is no impact on patient safety or on the product’s existing global regulatory filings and emphasized its commitment to reliable global supply of this metabolic therapy. Management will host a conference call on July 9, 2026, to discuss the situation.
Dr. Reddy’s Laboratories Limited has informed shareholders about its 42nd Annual General Meeting and related shareholder communication. The AGM will be held on July 23, 2026 at 11:00 a.m. IST through video conferencing and other audio-visual means.
The company’s Notice and Integrated Annual Report for financial year 2025-26 are available online via a provided web link and QR code, and letters are being sent to shareholders without registered email addresses. The board has proposed a final dividend of ₹8 per equity share, with a record date of July 10, 2026 and payment on or before July 30, 2026.
The filing also provides e-voting details, with eligibility set by a cut-off date of July 16, 2026 and remote e-voting available from July 19 to July 22, 2026. Shareholders are requested to update their KYC details with their depository participants or the company’s registrar and transfer agent, and contact details for the registrar are provided for queries and service requests.
Dr. Reddy’s Laboratories Limited reports that the United States Food & Drug Administration has completed a Pre-License Inspection at its biologics manufacturing facility in Bachupally, Hyderabad. The inspection, conducted from June 16 to June 25, 2026, resulted in a Form 483 with seven observations.
The company states it will address these observations within the stipulated timeline. This update follows earlier inspections and related disclosures made to stock exchanges on October 12, 2023 and September 13, 2025, and is provided for information of investors and exchanges.
Dr. Reddy’s Laboratories Limited has scheduled a Board meeting for July 22, 2026 to consider the company’s unaudited standalone and consolidated financial results for the quarter ending June 30, 2026. The company also announced that its trading window for dealing in its securities will be closed from June 24, 2026 to July 24, 2026, in line with insider trading regulations.